Related Experiment Video

Updated: Aug 8, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[When can the treatment of isolated systolic hypertension be avoided?]

U M Vischer1, A Benetos

  • 1Hôpital de gériatrie 3, ch. Du Pont Bochet 1226 Thônex. ulrich.vischer@hcuge.ch

Revue Medicale Suisse
|May 6, 2006
PubMed

Insights

Treating isolated systolic hypertension in older adults lowers cardiovascular risk, but may increase mortality in the very old. Benefits for dementia risk are unclear, requiring individualized patient care.

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Context:

  • Isolated systolic hypertension (ISH) is common in the elderly.
  • ISH treatment can reduce cardiovascular (CV) events, especially in those with diabetes or prior CV history.

Purpose:

  • To evaluate the benefits and risks of treating ISH in the elderly, particularly the very old (>80-85 years).
  • To assess the impact of ISH treatment on stroke risk, global mortality, and dementia.
  • To emphasize the importance of accurate diagnosis and individualized treatment decisions.

Summary:

  • ISH treatment in the elderly reduces CV risk but may increase overall mortality in those over 80-85 years.
  • While stroke risk is decreased, the effect on dementia risk remains uncertain.
  • Accurate ISH diagnosis via ambulatory blood pressure monitoring is crucial.
  • Treatment benefits are duration-dependent, and limited life expectancy may reduce impact.
  • Anti-hypertensive therapy decisions require individual assessment and patient autonomy.

Impact:

  • Provides critical insights for managing hypertension in elderly populations.
  • Highlights the need for personalized treatment strategies considering age and comorbidities.
  • Informs clinical guidelines regarding the risks and benefits of ISH treatment in very old individuals.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...